<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03133351</url>
  </required_header>
  <id_info>
    <org_study_id>PCM-001</org_study_id>
    <nct_id>NCT03133351</nct_id>
  </id_info>
  <brief_title>Reference Range Analysis of the Entegrion Point of Care Coagulation Monitor (PCM™) in Healthy Volunteers</brief_title>
  <official_title>Reference Range Analysis of the Entegrion Point of Care Coagulation Monitor (PCM™) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Entegrion, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Entegrion, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to define the PCM normal laboratory range.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PCM Clotting Time (CT)</measure>
    <time_frame>Testing to be initiated within 4 minutes of sample collection</time_frame>
    <description>To define the PCM normal laboratory reference range, PCM clotting time (CT) will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clot Formation Time (CFT)</measure>
    <time_frame>Testing to be initiated within 4 minutes of sample collection</time_frame>
    <description>To define the PCM normal laboratory reference range, clot formation time (CFT) will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alpha Angle (AA)</measure>
    <time_frame>Testing to be initiated within 4 minutes of sample collection</time_frame>
    <description>To define the PCM normal laboratory reference range, alpha angle (AA) will be measured.
To define the PCM normal laboratory reference range, clot formation time (CFT) will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Clot Firmness (MCF)</measure>
    <time_frame>Testing to be initiated within 4 minutes of sample collection</time_frame>
    <description>To define the PCM normal laboratory reference range, maximum clot firmness (MCF) will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>30-minutes Lysis after CT (LI30)</measure>
    <time_frame>Testing to be initiated with 4 minutes of sample collection, with result available 30 minutes after CT</time_frame>
    <description>To define the PCM normal laboratory reference range, 30-minutes lysis after CT (LI30) will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>45-minutes Lysis after CT (LI45)</measure>
    <time_frame>Testing to be initiated within 4 minutes of sample collection, with result available 45 minutes after CT</time_frame>
    <description>To define the PCM normal laboratory reference range, 45-minutes lysis after CT (LI45) will be measured.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Coagulation</condition>
  <arm_group>
    <arm_group_label>PCM</arm_group_label>
    <description>All enrolled subjects will have a blood sample tested using PCM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PCM</intervention_name>
    <description>A fresh whole blood sample will be tested by PCM to determine the reference range.</description>
    <arm_group_label>PCM</arm_group_label>
    <other_name>Point of Care Coagulation Monitor</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years old

          2. Body Mass Index (BMI) ≥ 19 and ≤ 30 kg/m2m with body weight ≥ 50 kg (106 lb)

          3. Normal vital signs at screening

        Exclusion Criteria:

          1. Current daily tobacco use or previous recreational drug use

          2. Pregnant or lactating at the time of the study

          3. Currently taking any medications known to affect coagulation

          4. History of excessive bleeding from minor trauma that required medical attention,
             spontaneous nose bleeds that required medical attention or multiple spontaneous
             abortions, liver disease, blood related diseases, congenital or acquired
             coagulopathies or thromboembolic diseases

          5. Current diagnosis of cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>120 Males and 120 Females</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Entegrion, Inc.</last_name>
    <phone>919-536-1500</phone>
    <email>shammonds@entegrion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

